Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Opthea ( (AU:OPT) ) has shared an update.
Opthea Limited has issued 82 million unquoted options under an employee incentive scheme, as disclosed in an Appendix 3G filing with the ASX dated 19 December 2025. The options, which carry various expiry dates and exercise prices and are not intended to be quoted on the ASX, expand the company’s pool of employee equity incentives and may increase potential future dilution while aligning staff remuneration more closely with shareholder value over the long term.
The most recent analyst rating on (AU:OPT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Opthea stock, see the AU:OPT Stock Forecast page.
More about Opthea
Opthea Limited is an Australian biotechnology company listed on the ASX that develops biotherapeutic treatments, primarily focused on ophthalmic diseases. The company’s activities center on advancing drug candidates in clinical development to address significant unmet medical needs in eye care markets.
Technical Sentiment Signal: Sell
Current Market Cap: A$738.8M
See more insights into OPT stock on TipRanks’ Stock Analysis page.